The innate immune response to invading viruses is critical for the mounting of protective immunity, in which type I interferons (IFN), for example, IFN-α and β, are potent effector molecules. 1 Most cell types, particularly fibroblasts and epithelial cells, produce IFN-β, whereas hematopoietic cells, notably plasmacytoid dendritic cells, are the predominant sources of IFN-α. IFNs potently stimulate a variety of innate and adaptive immune cells, including macrophages, NK cells and T cells. The binding of type I IFN to its cognate receptor triggers the activation of the Janus kinase signal transducer and activator of transcription pathway, which results in the transcription of IFNstimulated genes that play key roles in host resistance to viral infections. The production of type I IFN is finely controlled by diverse host factors to trigger tailored immune responses that are suitable for host defense and survival. 1 This balanced production of type I IFN is critical for protection against viral infections, as their defective or excessive production leads to chronic infection or autoimmune and/or inflammatory diseases, respectively. In this respect, a greater understanding of the mechanisms and the identification of novel host factors that govern type I IFN production are important for elucidating host antiviral defenses and developing rational therapies for effective viral eradication that do not damage the host.
Innate antiviral immunity is initiated by the engagement of pattern recognition receptors (PRRs) that are present on the cell surface or within distinct intracellular compartments. 2, 3 The prototypical pathogen-associated molecular patterns of viruses are nucleic acids, for example, viral RNA and DNA, which can be recognized by a number of PRRs, such as endosomal Toll-like receptors (TLRs), cytosolic RIG-I-like receptors (RLRs) and cytosolic sensors of DNA, including cyclic GMP-AMP synthase (cGAS), DExD/H box family helicase (DDX41) and IFN-inducible protein (IFI16). 2, 3 With the exceptions of some viruses that possess the ability to directly enter the cytoplasm, for example, HIV and herpes simplex virus (HSV), the entry of viruses is mainly mediated by an endocytic pathway. Endocytosed viruses are first trafficked to endocytic compartments called endosomes and then penetrate the endosomal membrane to release their nucleic acids into the cytoplasm. These viral nucleic acids in the endosome are recognized by the RNA sensors TLR3, TLR7 and TLR8 and the DNA sensor TLR9, whereas those in the cytoplasm are recognized by the RNA sensors RIG-I and MDA5 and the DNA sensor cGAS. Upon recognition of viral nucleic acids, these PRRs recruit adapter molecules, such as MyD88, TRIF, MAVS and STING. The MyD88-dependent responses of TLR7, TLR8 and TLR9 lead to the expression of type I IFN via IRF7 activation, and the TRIF recruited by TLR3, MAVS recruited by RLRs and STING recruited cGAS trigger the activation of the IKK-related kinases IKKε and TBK1, which drive IRF3 activation and type I IFN production.
In a recent study published in Nature Immunology, Wang et al. 4 demonstrated a novel role of YAP in antagonizing innate antiviral immunity via the regulation of type I IFN production in response to DNA and RNA viruses. YAP deficiency upregulated IFN-β expression at both the RNA and protein levels and reduced titers of the Sendai virus, vesicular stomatitis virus and HSV-1 in vitro and in vivo. These results were confirmed using various cellular and experimental systems, including knockdown of the gene in HEK293T cells and macrophages, heterozygous systemic knockout of the gene, myeloid cell-specific knockout of the gene and homozygous knockin mutation of the gene in HEK293T and A549 lung carcinoma cells. YAP and TAZ have been extensively investigated in cancer biology because they play important roles in cancer initiation, progression and metastasis. 5 These proteins are transcriptional coactivators downstream of the Hippo pathway, which is highly conserved in mammals. The core components of the Hippo pathway include two distinct kinases, that is, MST1/2 and LATS1/2, and two transcriptional coactivators, that is, YAP and TAZ. 6 When the Hippo pathway is active, MST1/2 activates LATS1/2 via phosphorylation; the activated LATS1/2 then inhibits YAP/ TAZ via phosphorylation-mediated cytoplasmic sequestration and degradation (Figure 1 ). The interactions of YAP/ TAZ with transcription factors of the TEAD family are critical for their transcriptional regulatory effect. However, in this study, the inhibitory effect of YAP on IFN-β expression was independent of its transcription regulatory function, as YAP4, a transcriptionally inactive isoform that lacks a TEAD-interacting domain, also sequestered IRF3 specifically in the cytoplasm and thereby blocked the IRF3-dependent antiviral program in the nucleus (Figure 1) . Notably, YAP itself was subjected to posttranslational modification in the cytoplasm upon the triggering of innate antiviral immunity, which indicated a physiological relevance of YAP deficiency upon virus infection. The phosphorylation of YAP at Ser403 by activated IKKε rather than TBK1 was essential for the regulatory role of YAP in antiviral immunity, as this process triggered the lysosomal degradation of YAP and the subsequent relief of the YAP-mediated inhibition of IFN-β expression. Further, this lysosomal degradation of YAP was not mediated by the Hippo pathway kinases LATS1/2, which promote the phosphorylation and ubiquitin-mediated proteasomal degradation of YAP.
This study is the first report on the role of the oncoprotein YAP in restraining innate antiviral immune responses. Notably, YAP4 was as effective, if not more effective, as a regulator as transcriptionally active YAP2, which suggests that the TEAD family members and transcriptional regulation by YAP are dispensable to the antiviral immunity of innate immune cells. Additional investigation is required to understand the roles of each isoform of YAP, which has nine isoforms, thus raising the possibility of isoform-specific functions of YAP in different contexts. It is possible that the YAP1/2 isoforms play a role in organ size control and tissue homeostasis and that YAP4 might play a specific role in innate antiviral responses. It is also interesting to study the role of YAP isoforms in the control of activated immune cells and the size of secondary lymphoid organs because they need to be restored to the resting state after the clearance of viruses. These results could be applied to bacterial infections because cGAS-STING is stimulated by DNA in the cytosol of Mycobacterium tuberculosis (Mtb)-infected cells, 7 and TLR4-TRIF is stimulated by LPS from Gram-negative bacteria, and these pathways share downstream signaling cascades with sensors of viral nucleic acids. Consistent with the finding of YAP-mediated inhibition of innate immune responses, the activation of Yorkie, a homolog of YAP in Drosophila, leads to the decreased expression of antimicrobial peptides and increases the susceptibility to infection with Gram-positive bacteria. 8 Similarly, MST1/2 in the Hippo pathway, which negatively regulates YAP, triggers the activation of IRF3 in Mtb infection. 9 However, as the authors discussed, MST1, but not MST2, can directly inactivate IRF3 via an inhibitory phosphorylation and thereby repress the cytosolic antiviral defense; 10 these findings thus argue for an opposing role among components of the Hippo pathway in the regulation of innate immune responses.
It should be noted that virus infection can cause cancer through the modulation of YAP. The E6 protein from oncogenic strains of the human papilloma virus stabilizes the YAP protein, 11 and infection with Kaposi sarcomaassociated herpes virus activates YAP/ TAZ. 12 YAP/TAZ are normally inactive in healthy cells but are active in early neoplastic lesions. 5 Thus, the early downregulation of YAP as a host antiviral response or by therapeutic means could help clear the virus via type I IFN expression as well as prevent the development of cancer. Given that YAP is an oncoprotein in diverse tumor cells and a negative regulator of IFN-β expression with anti-cancer potential, therapeutic targeting of YAP could be a potential strategy to treat cancer associated with the dysregulation of YAP and/or type I IFN. For example, verteporfin, a porphyrin family molecule that disrupts YAP-TEAD interactions, has shown anti-tumor effects or the ability to sensitize tumor cells to chemotherapy drugs in various tumor models. 13, 14 However, targeting components in the Hippo pathway, including YAP, for cancer therapy should be investigated with extra precautions because there are paradoxical results on cancer control in the net effects of Hippo pathway modulation. Although the Hippo pathway limits organ size and suppresses tumor formation, a recent study demonstrated that an inactivation of the Hippo pathway could represses tumor growth by increasing tumor immunogenicity despite a proliferative and survival advantage to the tumor cells. 15 Taken together, the specific functions of the core components, including their isoforms in the Hippo pathway and the regulatory mechanisms that function among them, await further research. If successfully uncovered, this information could be exploited for the development of rational therapeutic strategies for various human diseases associated with the dysregulation of components of the Hippo pathway, including YAP.
